Clinical Trial Update: ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of vemurafenib and cobimetinib for Stage IIIB-C melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cobimetinib (Cotellic) (cobimetinib)
• Vemurafenib (Zelboraf) (vemurafenib)

Snippet

Sponsor: Inova Health Care Services | Conditions: Stage IIIB-C Melanoma | Phase 2 | Status: WITHDRAWN